[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Yves Agid, Niall Quinn, F Lhermitte
Abstract
Yves Agid, Niall Quinn, F Lhermitte
Abstract
Thirty-seven parkinsonian patients treated with bromocriptine +/- domperidone were examined eighteen months later. Fifteen continued the same treatment; 10 also received L-DOPA plus a peripheral DOPA-decarboxylase-inhibitor; the others resumed L-DOPA therapy. Thus, by limiting peripheral side effects, domperidone permits effective doses of bromocriptine.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Thirty-seven parkinsonian patients treated with bromocriptine +/- domperidone were examined eighteen months later. Fifteen continued the same treatment; 10 also received L-DOPA plus a peripheral DOPA-decarboxylase-inhibitor; the others resumed L-DOPA therapy. Thus, by limiting peripheral side effects, domperidone permits effective doses of bromocriptine.
Key concepts: Bromocriptine, Domperidone, Medicine, Decarboxylase inhibitor, Peripheral, Dopaminergic, Parkinson's disease, Levodopa